Skip to content
Clinical Trials – home

Hospital Santa Maria Della Misericordia

Research site

Italy Piazzale Giorgio Menghini 1, 06129 Perugia, Italy

  • 64 trials recruiting
  • Non-small cell lung cancer · Chronic lymphocytic leukaemia · Acute myeloid leukaemia
  • Adults and children

About Specializations

Hospital Santa Maria Della Misericordia in Perugia, Italy specialises in clinical trials of conditions such as Non-small cell lung cancer, Chronic lymphocytic leukaemia, Acute myeloid leukaemia, Dementia Alzheimer's type, and other specialisations. This site conducts important research.

Main research areas of the site

Oncology and Hematologic Malignancies

At Hospital Santa Maria Della Misericordia, a major share of research focuses on neoplasms and blood cancers, with studies in non-small cell lung cancer, melanoma, lymphoma, leukemia, multiple myeloma, and breast cancer. The trials are largely aimed at testing new cancer therapies, improving treatment combinations, and understanding how to better control disease recurrence and progression.

  • Research in advanced and resected lung cancer, including targeted and immunotherapy approaches
  • Studies in acute myeloid leukemia, acute lymphoblastic leukemia, and other leukemias with risk-adapted treatment strategies
  • Trials in lymphoma, multiple myeloma, and related hematologic cancers to improve response and durability of benefit
  • Investigations in melanoma and breast cancer focused on better disease control after standard treatment

Overall, the site supports a broad and active oncology program that combines precision medicine, immunotherapy, and new treatment options for both solid tumors and blood cancers.

Cardiovascular and Metabolic Research

The site also conducts important trials in cardiovascular diseases and nutritional and metabolic diseases, especially heart failure, atrial fibrillation, atherosclerotic cardiovascular disease, type 2 diabetes, obesity, and elevated lipoprotein(a). These studies aim to evaluate whether newer treatments can reduce complications, improve long-term outcomes, and lower the burden of chronic disease.

  • Trials in heart failure and related cardiovascular conditions to reduce events and improve clinical stability
  • Research on atrial fibrillation and coronary disease to refine prevention and treatment strategies
  • Studies in obesity, type 2 diabetes, and lipid disorders to address cardiometabolic risk
  • Work on lipoprotein(a) and atherosclerosis to better understand cardiovascular risk reduction

This therapeutic area reflects a strong interest in long-term disease prevention and in treatments that can support better heart and metabolic health.

Neurology, Eye Disease, and Immune-Mediated Conditions

Clinical research at the site spans nervous system diseases, eye diseases, and immune system diseases, including Alzheimer’s disease, migraine, multiple sclerosis, age-related macular degeneration, atopic dermatitis, prurigo nodularis, and rheumatoid arthritis. The purpose of these trials is often to improve symptom control, slow disease worsening, or test new options for chronic inflammatory and degenerative disorders.

  • Studies in Alzheimer’s disease and cognitive impairment focused on slowing decline and supporting brain health
  • Trials for migraine and headache disorders aimed at prevention and better symptom relief
  • Research in age-related macular degeneration and other eye conditions to preserve vision
  • Immune and inflammatory disease studies in atopic dermatitis, rheumatoid arthritis, and related skin and joint disorders

Within the Department of Medicine and Surgery, this work highlights a broad commitment to improving both quality of life and disease control in chronic conditions.

Respiratory, Skin, and Multisystem Disease Studies

The research portfolio at Hospital Santa Maria Della Misericordia also includes respiratory tract diseases, skin and connective tissue diseases, and other complex inflammatory conditions such as idiopathic pulmonary fibrosis, small-cell lung cancer, hidradenitis suppurativa, acne vulgaris, and systemic sclerosis. These trials are designed to evaluate new therapies, improve disease management, and address conditions with limited treatment options.

  • Research in idiopathic pulmonary fibrosis aimed at slowing lung function decline
  • Studies in small-cell lung cancer and other respiratory cancers to improve treatment effectiveness
  • Trials in hidradenitis suppurativa, acne vulgaris, and related skin disorders to reduce inflammation and symptoms
  • Investigations in systemic sclerosis and other multisystem immune conditions to better manage chronic disease burden

With many investigators contributing across these areas, the site supports a diverse portfolio that connects oncology, inflammation, and chronic organ disease research.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Piazzale Giorgio Menghini 106129 PerugiaItaly
Recruiting now
64 trials
Conditions studied
130

More sites in PerugiaItaly

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

207 clinical trials

Study of VHB937 to evaluate its effects on cognition and function in people with early Alzheimer's Disease over 72 weeks

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:VHB937
  • Sponsor:Novartis Pharma AG

Study on Selatogrel for Preventing Heart Attack in Patients with Recent Heart Attack History

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Selatogrel
  • Sponsor:Viatris Innovation GmbH

Zenagamtide versus semaglutide: a study of blood sugar and weight reduction in adults with type 2 diabetes inadequately controlled on metformin and/or SGLT2 inhibitor

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Semaglutide
  • Sponsor:Novo Nordisk A/S

Adjuvant Therapy with RO7435846 (divarasib) versus Pembrolizumab or Nivolumab or Observation in Patients After Surgery for Stage II‑III KRAS G12C NSCLC

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Divarasib
  • Sponsor:F. Hoffmann-La Roche AG

Colorectal cancer+2

Recruiting

Study of RMC-6291 with ivonescimab drug combination in patients with advanced RAS‑mutated solid tumors

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Revolution Medicines Inc.

Nipocalimab in Adults with Moderate to Severe Systemic Lupus Erythematosus

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Nipocalimab
  • Sponsor:Janssen Cilag International

Graves' disease

Recruiting

Long-Term Study of Imeroprubart in Adults With Graves' Disease

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Imeroprubart
  • Sponsor:Immunovant Sciences GmbH

Cenegermin Eye Drops for Persistent Corneal Epithelial Defect in Patients with Persistent Corneal Epithelial Defect

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cenegermin
  • Sponsor:Dompe' Farmaceutici S.p.A.

Study of blinatumomab and a drug combination for older adults with newly diagnosed Philadelphia-negative B-cell precursor Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Asparaginase
  • Sponsor:Amgen Inc.

Comparing sotorasib and pembrolizumab with chemotherapy for patients with advanced non-small cell lung cancer and a KRAS G12C mutation

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Amgen Inc.

A study of mRNA-4157 and a drug combination for patients with stage IV non-small cell lung cancer

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Merck Sharp & Dohme LLC

A study to evaluate the effect of orforglipron on cardiovascular health in adults with atherosclerotic cardiovascular disease and/or chronic kidney disease

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Orforglipron hemicalcium
  • Sponsor:Eli Lilly & Co.
Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.